BioEngine Bio Raises Tens of Millions of RMB in Angel+ Round Led by Tiantu Investment

PAM2LBiotechnologies, an innovative enterprise specializing in the R&D and application of biomaterials, announced today that it has completed a tens-of-millions-yuan Angel+ round of financing. The round was led by TIANTU CAPITAL, with Shenzhen Co-stone Venture Investment Management Company Limited participating as a co-investor. The funds raised will be primarily used to expand the R&D center and construct a pilot-scale production platform.

PAM2LBiotechnologies, established in 2021 by Dr. Zhong Chao, a researcher at the Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences, and recipient of the National Science Fund for Distinguished Young Scholars, is driven by its dual-core technologies of synthetic biology and machine learning (BT-IT). The company is dedicated to developing bio-based materials and related products, providing customers with safe and efficient green solutions. Currently, its core product pipeline primarily includes protein- and polysaccharide-based materials, which are widely applied in the pharmaceutical, cosmetics, and food industries.

In December 2021, PAM2LBiotechnologies secured nearly $5 million in angel-round funding from Source Code Capital. Previously, PAM2LBiotechnologies had been certified as a “synthetic biology enterprise” by Guangming District, Shenzhen—the first district-level administrative unit in China to issue local policies on synthetic biology. The company serves as a prime example of the “upstairs-downstairs innovation complex” model pioneered by the Shenzhen Institute of Advanced Technology, Chinese Academy of Sciences, wherein research institutes operate upstairs and enterprises operate downstairs.

Wei Guoxing, Partner at TIANTU CAPITAL“He stated, ‘In today’s increasingly competitive downstream consumer market, synthetic biology—seeking solutions from the upstream supply chain—has become a key investment focus for Tiantu Capital. We are optimistic about PAM2LBiotechnologies’ interdisciplinary expertise in synthetic biology and biomaterials. Leveraging Shenzhen Guangming District’s major synthetic biology infrastructure facilities, the company is continuously driving the gradual application of new high-value materials and coating technologies across consumer goods, industrial products, medical devices, and biopharmaceuticals. We are pleased to serve as the lead investor in this round and will leverage Tiantu Capital’s extensive downstream consumer market presence to jointly advance the commercialization of multiple product pipelines, establishing PAM2LBiotechnologies as a benchmark enterprise in Shenzhen’s synthetic biology sector.’”

Huang Yiqun, Partner at Co-stone Capital“Synthetic biology is a key scientific and technological discipline that translates fundamental research in biotechnology into tangible social productivity. Innovations and breakthroughs in its underlying tools are gradually emerging as a new paradigm for human creation, poised to transform every individual’s life in the future. As one of the most promising frontiers in modern science, the growth of synthetic biology enterprises carries profound social significance. We have full confidence in PAM2LBiotechnologies and will continue to support its development, expecting the company to become a cornerstone of China’s synthetic biology industry and create greater social value.”